StockData
GENELUX Corp logo

GENELUX Corp (GNLX) stock

GNLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 5/30
$2.00+0.08 (+4.17%)

Close on Nov 17, 2026Market cap $90.49MP/E –Yield –

Genelux operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Genelux's operating cash flow for the twelve months ending Jun 30, 2026 was -$25.28M. For fiscal 2025 it was -$25.27M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$25.27M–
FY2024Dec 31, 2024-$21.23M–
FY2023Dec 31, 2023-$20.28M–
FY2022Dec 31, 2022-$3.57M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$6.44M–
Q1 FY2026Mar 31, 2026-$6.06M–
Q4 FY2025Dec 31, 2025-$6.20M–
Q3 FY2025Sep 30, 2025-$6.58M–
Q2 FY2025Jun 30, 2025-$7.06M–
Q1 FY2025Mar 31, 2025-$5.44M–
Q4 FY2024Dec 31, 2024-$4.30M–
Q3 FY2024Sep 30, 2024-$5.75M–
Q2 FY2024Jun 30, 2024-$6.82M–
Q1 FY2024Mar 31, 2024-$4.35M–
Q4 FY2023Dec 31, 2023-$6.91M–
Q3 FY2023Sep 30, 2023-$3.36M–
Q2 FY2023Jun 30, 2023-$5.42M–
Q1 FY2023Mar 31, 2023-$4.59M-262.5%
Q4 FY2022Dec 31, 2022-$1.52M–
Q3 FY2022Sep 30, 2022-$2.47M–
Q2 FY2022Jun 30, 2022-$2.41M–
Q1 FY2022Mar 31, 2022$2.83M–

More Genelux figures

See a number that looks wrong?